Formalizes 1-for-50 Reverse Stock Split, Details Timetable for Share Consolidation

summarizeSummary

Alterity Therapeutics has formally notified of a 1-for-50 reverse stock split, consolidating its ordinary shares and options, with a record date set for June 4, 2026.

check_boxKey Events

• 1-for-50 Reverse Stock Split Confirmed

  The company formally announced a 1-for-50 reverse stock split, consolidating every 50 existing shares into 1 new share. This follows the general meeting proposal announced on April 29, 2026.

• Impacts All Securities

  The consolidation applies to all ordinary fully paid shares (ATH) and numerous outstanding options, adjusting their quantities and exercise prices proportionally.

• Timetable Established

  Key dates include a security holder meeting on May 29, 2026, a record date of June 4, 2026, and trading in post-consolidation securities commencing on a deferred settlement basis on June 3, 2026.

auto_awesomeAnalysis

This filing formalizes the previously announced proposal for a highly aggressive 1-for-50 reverse stock split, which will significantly reduce the number of outstanding shares and increase the per-share price. While often undertaken to meet exchange listing requirements or attract institutional investors, such a substantial consolidation is typically viewed negatively by the market as it can signal underlying financial challenges or precede further dilutive capital raises. Investors should monitor the stock's performance post-split and any subsequent financing activities.